politics
Is this the end of costly and harmful pharmaceutical advertising?
Why this matters: political developments that affect policy direction and public trust.
Direct-to-consumer pharmaceutical advertising is under increasing political pressure, with bipartisan legislation being introduced to ban or restrict the practice, and states considering bills to deny tax deductions for pharmaceutical advertising expenses.
Read full story on The Hill → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from The Hill alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop